Search results for "Adverse effect"

showing 10 items of 1065 documents

Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.

2015

Background Randomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe+simvastatin, on mortality and morbidity outcomes. Methods and Findings We searched for RCT on Ezetimibe using MEDLINE, CCTR, EMBASE, ClinicalTrials.gov databases up to December 2013, Merck and Novartis online registers, and personal communications. Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same …

MaleSimvastatinmedicine.medical_specialtylcsh:MedicineComorbidityPharmacologyPlacebolaw.inventionEzetimibeRandomized controlled triallawCardiovascular DiseaseCause of DeathInternal medicineAnticholesteremic AgentmedicineHumansAdverse effectlcsh:ScienceStrokeAgedRandomized Controlled Trials as TopicCause of deathMultidisciplinarybusiness.industryAnticholesteremic Agentslcsh:RMiddle AgedEzetimibemedicine.diseaseTreatment OutcomeCardiovascular DiseasesSimvastatinMeta-analysisDrug Therapy CombinationFemalelcsh:QbusinessResearch ArticleHumanmedicine.drugPLoS ONE
researchProduct

Cognitive and mood side effects of lower urinary tract medication

2019

Introduction: Muscarinic receptor antagonists, 5α-reductase inhibitors and α1-adrenoceptor antagonists are frequently used drug classes for the treatment of lower urinary tract symptoms including those of overactive bladder syndrome and benign prostatic enlargement/benign prostatic obstruction. Areas covered: The authors review the evidence for adverse effects of these drug classes on cognitive function, mood and other functions of the central nervous system and discuss such effects against the evidence for mechanistic plausibility. Expert opinion: Muscarinic antagonists carry a risk for impaired cognition and other brain functions that differs quantitatively between compounds, being highes…

MaleTamsulosinmedicine.medical_specialtyUrinary systemProstatic HyperplasiaMuscarinic Antagonists030204 cardiovascular system & hematology03 medical and health sciences5-alpha Reductase InhibitorsCognition0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsTamsulosinInternal medicinemedicineAnimalsHumansDementiaPharmacology (medical)OxybutyninAdverse effectDose-Response Relationship DrugUrinary Bladder Overactivebusiness.industryGeneral Medicinemedicine.diseaseDiscontinuationAffectMood030220 oncology & carcinogenesisAdrenergic alpha-1 Receptor Antagonistsbusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

Opioid plasma concentration during switching from morphine to methadone: Preliminary data

2003

Opioid switching is often used to improve the opioid response in cancer patients experiencing poor analgesia or adverse effects. However, no data are available on plasmatic changes of opioids and their metabolites during these phases, and whether there exists a relationship with the clinical events. In a prospective study of 10 consecutive cancer patients on oral morphine but with uncontrolled pain (greater >4 on a numerical scale of 0 to 10) and/or moderate to severe opioid adverse effects (on a level of 2 and 3 of a verbal scale) and not responsive to adjuvant medications, switching to oral methadone was performed using a fixed ratio of 5:1, leaving extra-doses of 1/5 of the daily dose of…

MaleTime FactorsAdministration OralAdverse effectDrug Administration ScheduleNeoplasmsBlood plasmamedicineHumansProspective StudiesCancer painProspective studyProspective cohort studyAdverse effectAgedDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedPain IntractableAnalgesics OpioidTreatment OutcomeOpioidOncologyAnesthesiaToxicitySwitchingMorphineFemaleAnalgesiabusinessCancer painMethadonemedicine.drugMethadone
researchProduct

Morbidity and mortality after anaesthesia in early life:results of the European prospective multicentre observational study, neonate and children aud…

2021

Background: Neonates and infants requiring anaesthesia are at risk of physiological instability and complications, but triggers for peri-anaesthetic interventions and associations with subsequent outcome are unknown. Methods: This prospective, observational study recruited patients up to 60 weeks' postmenstrual age undergoing anaesthesia for surgical or diagnostic procedures from 165 centres in 31 European countries between March 2016 and January 2017. The primary aim was to identify thresholds of pre-determined physiological variables that triggered a medical intervention. The secondary aims were to evaluate morbidities, mortality at 30 and 90 days, or both, and associations with critical …

MaleTime FactorsHealth StatusComorbidityIntraoperative Complications/diagnosis/epidemiology/mortality/therapy0302 clinical medicinePostoperative Complications030202 anesthesiologyRisk Factorspatient safetyMedicineAnesthesiaProspective StudiesProspective cohort studyIntraoperative ComplicationsMedical Auditddc:617Incidence (epidemiology)IncidenceAge FactorsGestational agecritical eventsEuropeAnesthetics/adverse effectsqualityAnesthesiaSurgical Procedures OperativeoutcomeFemaleInfant PrematureGestational AgeAnesthesia/adverse effects/mortalityRisk AssessmentEurope/epidemiology03 medical and health sciencesHumansAnestheticsquality.business.industryPostoperative Complications/diagnosis/epidemiology/mortality/therapyPostmenstrual AgeInfant NewbornInfantmedicine.disease3126 Surgery anesthesiology intensive care radiologyComorbidityneonatesClinical trialSurgical Procedures Operative/adverse effects/mortalityAnesthesiology and Pain MedicineBlood pressureObservational studycritical eventneonatebusiness
researchProduct

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

2017

Background and purpose While the efficacy and safety of combined tiotropium and olodaterol in patients with COPD was established in a large clinical trial program, it is important to assess whether clinical data can be applied to geographic patient groups, particularly for East Asian patients who may have a different phenotypic profile to the global trial population. This study aimed to compare the lung function and safety profiles of tiotropium/olodaterol and monocomponents in East Asian and global populations from the TONADO® trials. Materials and methods In the replicate, double-blind, parallel-group, active-controlled, randomized, 52-week, Phase III TONADO studies, patients received tio…

MaleTime FactorsHealth StatusVital CapacityCholinergic AntagonistsPulmonary function testingPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineForced Expiratory Volume030212 general & internal medicineLungLung functionOriginal ResearchCOPDeducation.field_of_studypulmonary functionOlodaterolArea under the curveGeneral MedicineMiddle AgedhumanitiesBronchodilator AgentsDrug CombinationsTreatment OutcomeArea Under CurveFemaleChinamedicine.medical_specialtyPopulationInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health sciencesAsian PeopleDouble-Blind MethodInternal medicinemedicineHumansCOPDTiotropium BromideAdverse effecteducationAdrenergic beta-2 Receptor AgonistsAgedbusiness.industryRecovery of Functionmedicine.diseaseBenzoxazinesrespiratory tract diseasesClinical trial030228 respiratory systemchemistryQuality of Lifeadverse effectsTONADO®businesshuman activitiesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Hyperalgesia and opioid switching

2005

Opioids, intended to abolish pain, can unexpectedly produce hyperalgesia, particularly during rapid opioid escalation. Opioid switching could be a therapeutic option in a condition of opioid-induced tolerance or hyperalgesia, but conversion ratios between opioids are difficult to apply in this context and require strict surveillance and expertise. This situation is challenging, because the rapid escalation of opioid doses, possibly due to the development of opioid-induced tolerance, can cause hyperalgesia. To avoid this adverse effect, clinicians need to refine their assessment of pain treatment and consider opioid switching. The authors present a case report in which switching from fentan…

MaleTime FactorsPainContext (language use)Drug Administration ScheduleFentanyl03 medical and health sciences0302 clinical medicine030502 gerontologymedicineHumansAdverse effectPain Measurementbusiness.industryPatient SelectionPalliative CareSarcomaDrug ToleranceGeneral MedicineMiddle AgedThoracic NeoplasmsAnalgesics OpioidFentanylTherapeutic EquivalencyOpioidHyperalgesia030220 oncology & carcinogenesisAnesthesiaHyperalgesiaDrug Monitoringmedicine.symptom0305 other medical scienceCancer painbusinessMethadonemedicine.drugMethadoneAmerican Journal of Hospice and Palliative Medicine®
researchProduct

Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation

2018

Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains controversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to assigned strategies. ........................................................................................................................................................... Methods and results Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data were reported. Among rate control strategies, beta-blockers …

MaleTime FactorsRate controlAction PotentialsPilot Projects030204 cardiovascular system & hematologyAmiodaroneAction Potentials/drug effectsHeart Conduction System/drug effectsCardiologists0302 clinical medicineHeart RateRisk FactorsCause of DeathAtrial Fibrillation030212 general & internal medicineRegistriesPractice Patterns Physicians'Cause of deathAged 80 and overAll-cause death; Atrial fibrillation; Major adverse events; Rate control; Registry; Rhythm controlHeart Rate/drug effectsAtrial fibrillationMiddle AgedEuropeTreatment OutcomeCohortCardiologyHealthcare Disparities/trendsRhythm controlFemaleCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsCardiologists/trendsmedicine.drugmedicine.medical_specialtyMajor adverse eventsRegistryAll-cause deathAnti-Arrhythmia Agents/adverse effectsEurope/epidemiology03 medical and health sciencesHeart Conduction SystemPhysiology (medical)Internal medicineHeart ratemedicineAtrial Fibrillation/diagnosisHumansHealthcare DisparitiesAdverse effectAgedbusiness.industryProportional hazards modelmedicine.diseaseAtrial fibrillationPractice Patterns Physicians'/trendsAtrial fibrillation • Rate control • Rhythm control • Major adverse events • All-cause death • RegistryPropensity score matchingbusiness
researchProduct

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian…

2014

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing-remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment. © Th…

MaleTime FactorsThyroid GlandAutoimmunityAdverse effectmedicine.disease_causemultiple sclerosisGastroenterologythyroidAutoimmunityImmunosuppressive AgentRisk FactorsRetrospective StudiePrevalenceinterferon betaThyroidadverse effects; autoimmunity; glatiramer acetate; interferon beta; thyroid; multiple sclerosisMiddle AgedTreatment Outcomemedicine.anatomical_structureItalyNeurologymultiple sclerosiThyroid autoimmunityCohortFemaleSettore MED/26 - NeurologiaThyroid functionImmunosuppressive AgentsInterferon beta-1aHumanInterferon beta-1bmedicine.drugAdultmedicine.medical_specialtyTime FactorThyroid DiseaseRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicinemedicineHumansGlatiramer acetateAdverse effectRetrospective Studiesbusiness.industryRisk FactorMultiple sclerosisGlatiramer Acetatemedicine.diseaseThyroid DiseasesImmunologyadverse effectsNeurology (clinical)business
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: effect of experimental parameters and skin type on drug stability a…

2010

The aim of this study was to investigate the cathodal iontophoresis of dexamethasone sodium phosphate (DEX-P) in vitro and in vivo and to determine the feasibility of delivering therapeutic amounts of the drug for the treatment of chemotherapy-induced emesis. Stability studies, performed to investigate the susceptibility of the phosphate ester linkage to hydrolysis, confirmed that conversion of DEX-P to dexamethasone (DEX) upon exposure to samples of human, porcine and rat dermis for 7 h was limited (82.2+/-0.4%, 72.5+/-4.8% and 78.6+/-6.0% remained intact) and did not point to any major inter-species differences. Iontophoretic transport of DEX-P across dermatomed porcine skin (0.75 mm thic…

MaleTime FactorsVomitingSwineSkin AbsorptionPharmaceutical ScienceAntineoplastic AgentsPharmacologyAdministration CutaneousHigh-performance liquid chromatographyDexamethasoneGlucocorticoids/administration & dosage/pharmacokineticsDexamethasone Sodium PhosphatePharmacokineticsDrug StabilitySpecies SpecificityIn vivoAnimalsHumansSkin/metabolismVomiting/chemically induced/prevention & controlRats WistarGlucocorticoidsTransdermalSkinddc:615IontophoresisDose-Response Relationship DrugChemistryHydrolysisGeneral MedicineAntineoplastic Agents/adverse effectsPermeationIontophoresisRatsDose–response relationshipDexamethasone/administration & dosage/analogs & derivatives/pharmacokineticsBiotechnologyNuclear chemistry
researchProduct